
    
      To investigate safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity
      when ONO-4685 is administered by single-dose intravenous continuous infusion in Japanese and
      Caucasian healthy adult male subjects. In addition, in Japanese healthy adult male subjects,
      to investigate dosing condition of Keyhole limpet hemocyanin (KLH) and to investigate safety,
      tolerability, pharmacokinetics, pharmacodynamics and immunogenicity when ONO-4685 is
      administered by single-dose intravenous continuous infusion after treating with KLH.
    
  